Find clinical trials for Lymphoma in Columbus, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma

Leukemia

Non-Hodgkin Lymphoma

Lymphoid Leukemia

Diffuse Large B-Cell Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Columbus, OH, USA:

Epcoritamab and Rituximab for First-line Follicular Lymphoma

of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma...

Enrolling

Low Grade Non-Hodgkin's Lymphoma, Adult

Follicular Lymphoma

Drug: Rituximab

Drug: Epcoritamab

Phase 2

Reid Merryman, MD

Columbus, Ohio, United States and 3 other locations

DS-3201b in Participants With Lymphomas

DS-3201b is an experimental drug that is being investigated in clinical research.Adults with non-Hodgkin lymphoma (NHL) may be able to join ...

Active, not recruiting

Lymphoma, Malignant

Non-hodgkin Lymphoma

Drug: DS-3201b

Phase 1

Daiichi Sankyo

Columbus, Ohio, United States and 20 other locations

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary object...

Active, not recruiting

B Cell Lymphoma

Mantle Cell Lymphoma

Drug: Ibrutinib

Drug: Palbociclib

Phase 2

Alliance Foundation Trials

Columbus, Ohio, United States and 8 other locations

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting

Non-Hodgkin Lymphoma

Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis

Columbus, Ohio, United States and 66 other locations

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting

Non Hodgkin Lymphoma

Drug: acalabrutinib

Drug: rituximab (IV)

Phase 1, Phase 2